-
Mashup Score: 0Treatment for Relapsed or Refractory Multiple Myeloma: Care Team Perspectives on a Bispecific Antibody - 2 month(s) ago
Editor-in-Chief: Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC Oncology Issues, Article, Volume 40, Dr Noa Biran, Susan Kumka and Maribel Pereiras are paid consultants for Johnson & Johnson and must present information in accordance with US Food & Drug Administration (FDA) requirements applicable to Johnson & Johnson. Multiple myeloma remains incurable, and most patients will inevitably relapse and cycle through multiple lines of therapy.² The treatment landscape of relapsed or refractory multiple
Source: journals.accc-cancer.orgCategories: General Medicine News, NursingTweet
-
Mashup Score: 0Bringing Cancer Research to the Community: Strategic Approaches to Representative Oncology Clinical Trial Design - 2 month(s) ago
Editor-in-Chief: Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC Oncology Issues, Article, Volume 40, The oncology clinical research landscape is undergoing trans- formative changes, marked by patient-centered approaches and operational efficiency in the community setting. New strategies for clinical trial design seek to ensure that study populations reflect the true heterogeneity of all patients affected by cancer, thereby improving the generalizability and application of clinical research findings.
Source: journals.accc-cancer.orgCategories: General Medicine News, NursingTweet-
ACORI hosted the Community Inclusive Clinical Trial Design Summit in Fall 2024 to bring key stakeholders together to discuss ways to strategically reduce barriers to clinical trial participation. Read the highlights in this month’s Oncology Issues: https://t.co/OYPYjxccLl! https://t.co/UUmUGYg5GU
-
-
Mashup Score: 1Addressing Social Drivers of Health: A Quality Improvement Approach to Developing Oncology-Specific Screening Tools - 2 month(s) ago
Editor-in-Chief: Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC Oncology Issues, Article, Volume 40, Advancements in cancer diagnostics and precision medicine have ushered in significant breakthroughs for patients diagnosed with cancer. However, the conditions in which people live, work, and play—social determinants of health (SDOH), also referred to as social drivers of health—can be just as critical to an individual’s health outcome as factors like baseline health status, disease characteristics, and
Source: journals.accc-cancer.orgCategories: General Medicine News, NursingTweet-
To address the inequalities that result from social drivers of health, ACCC developed an oncology-specific screening tool and resource library to better equip multidisciplinary cancer care teams with the skills to identify and address barriers to care. https://t.co/mzQxbP6FtR https://t.co/pJFPfYdGem
-
-
Mashup Score: 0Bridging Oncology and Dermatology: Integrating Dermatologic Toxicity Management Into Routine Cancer Care - 2 month(s) ago
Editor-in-Chief: Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC Oncology Issues, Article, Volume 40, An estimated 50% o f patients with cancer experience disruptions in treatment due to dermatologic toxicity. Anticancer treatment strategies have grown in number and complexity in recent decades, as have the toxicity profiles associated with these therapeutic agents. The increasing use of novel cancer therapies—including molecular targeted therapies, immunotherapies, hormonal therapies, and combinations
Source: journals.accc-cancer.orgCategories: General Medicine News, NursingTweet-
Discover how integrating dermatologic expertise into oncology can prevent treatment disruptions and improve patient outcomes in the latest installment of Oncology Issues: https://t.co/ykPGGKdlTC. https://t.co/bBdoZFkdco
-
-
Mashup Score: 0Adverse Event Management for CDK Inhibitors in Hormone Receptor–Positive Breast Cancer - 2 month(s) ago
Editor-in-Chief: Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC Oncology Issues, Article, Volume
Source: journals.accc-cancer.orgCategories: General Medicine News, NursingTweet-
This month’s Oncology Issues features an overview of 3 CDK4/6 inhibitors recently approved for use in patients with breast cancer, including common adverse effects and tips to promote patient adherence. Read more: https://t.co/HixNgi8KU4. https://t.co/Hqlp9Kytxl
-
-
Mashup Score: 2An Innovative Program Addresses Housing Insecurity - 2 month(s) ago
Editor-in-Chief: Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC Oncology Issues, Article, Volume 40, At Montefiore Health System, a unique and impactful program is transforming how health care addresses 1 of the most significant social determinants of health: housing. Montefiore’s Housing at Risk Program (H@RP) goes beyond traditional medical care by offering essential support to patients who are homeless or at risk of losing their homes. Over the past 15 years, the program has evolved into a comprehensiv
Source: journals.accc-cancer.orgCategories: General Medicine News, NursingTweet-
Over the last 15 years, @MontefioreNYC's Housing at Risk Program has evolved into a comprehensive support system bridging the gap between medical care and social services. Read more about their impactful work in the latest Oncology Issues: https://t.co/7jEtP2hJxx. https://t.co/CP7KoiB9LY
-
-
Mashup Score: 0Creating a Community-Wide Safety Net with Centralized Tracking and Management of Incidental Lung Nodules - 2 month(s) ago
Editor-in-Chief: Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC Oncology Issues, Article, Volume 40, Lung cancer is the second most common cancer among men and women and the leading cause of cancer-related death, accounting for 20% of all cancer deaths. 1 Overall survival for lung cancer is still only 23%, largely because the majority of lung cancers are diagnosed at later stage. 2 Although survival is much higher for early-stage disease, only 26% of patients with lung cancer are diagnosed at a localized
Source: journals.accc-cancer.orgCategories: General Medicine News, NursingTweet-
To improve follow-up care for patients with incidental lung nodules, UCHealth implemented an AI solution to create standardized protocols that ensure all patients receive timely and consistent follow up. Learn how in this month’s Oncology Issues: https://t.co/4ndmtjwPKt. https://t.co/3OhdPNrOnv
-
-
Mashup Score: 0Operationalizing a Breakthrough Bladder Cancer Medication With a Multidisciplinary Approach: Insights From Nurse Leaders - 4 month(s) ago
Editor-in-Chief: Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC Oncology Issues, Article, Volume 40, Non–muscle-invasive bladder cancer is one of the most common forms of bladder cancer in the United States. Roughly 75% of bladder cancer cases are classified as non–muscle-invasive at diagnosis. 1 According to the American Cancer Society, bladder cancer is the fourth most common cancer in the US, with an estimated 83,190 new cases diagnosed in 2023 (about 63,070 in men and 20,120 in women). 2 While
Source: journals.accc-cancer.orgCategories: General Medicine News, NursingTweet-
The latest Oncology Issues is here! Read it now to learn about how Fox Chase Cancer Center (@FoxChaseCancer) implemented a novel treatment for non-muscle-invasive bladder cancer by leveraging a multidisciplinary team: https://t.co/ZKEFg0roYM. https://t.co/BcMEcQSKVc
-
-
Mashup Score: 0
Editor-in-Chief: Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC Oncology Issues, Article, Volume 39, Over the last 2 decades, the development of bispecific antibodies (BsAbs) has revolutionized cancer treat-ment. 1 Developed to address drug resistance and to improve treatment safety and efficacy, bispecific antibodies have 2 distinct binding domains that can bind to 2 antigens or epitopes simultaneously. Although BsAbs are a promising new therapeutic approach, especially for hematologic malignancies in
Source: journals.accc-cancer.orgCategories: General Medicine News, NursingTweet-
In the most recent Oncology Issues learn about ACCC’s educational initiative designed to assist multidisciplinary cancer care teams implement bispecific antibodies in the community oncology setting: https://t.co/WOVWoO5jDs. https://t.co/dzGJsckhuB
-
-
Mashup Score: 0Integrating Biomarker Testing into Metastatic Colorectal Cancer Care - 6 month(s) ago
Editor-in-Chief: Krista Nelson, LCSW, OSW-C, FAOSW, FAPOS, FACCC Oncology Issues, Article, Volume 39, Colorectal cancer ranks as the third most common cancer globally and is the second leading cause of cancer-related deaths in the US. 1 More than half of these cases are associated with modifiable risk factors, such as smoking, obesity, high alcohol consumption, and physical inactivity. Over the past few decades, the death rate from colorectal cancer has been declining due to better health behaviors,
Source: journals.accc-cancer.orgCategories: General Medicine News, NursingTweet-
To improve biomarker testing practices in metastatic colorectal cancer care, ACCC led a quality improvement initiative that significantly increased testing rates, reduced time to testing, & enhanced clinical workflows. Read more in Oncology Issues: https://t.co/ClibQzkfiN. https://t.co/ai2mCfQdeZ
-
Read the latest Oncology Issues to learn how a multiple myeloma treatment team integrated a bispecific antibody therapy in the community setting, enabling patients to receive high-quality care closer to home: https://t.co/BaTQNv7qGu. https://t.co/ILIkM93lAV